Company Description
FSD Pharma Inc., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development.
The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices.
In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property.
FSD Pharma Inc. is headquartered in Toronto, Canada.
| Country | Canada |
| Founded | 1998 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Zeeshan Saeed |
Contact Details
Address: First Canadian Place, 100 King Street West, Suite 4000 Toronto, A6 M5X 1A4 Ontario, Canada | |
| Phone | (416) 854-8884 |
| Website | fsdpharma.com |
Stock Details
| Ticker Symbol | HUGE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| CIK Code | 0001771885 |
| CUSIP Number | 35954B206 |
| ISIN Number | CA35954B4047 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Lakshmi P. Kotra BPHARM, Ph.D. | Chief Executive Officer of Lucid and Director |
| Zeeshan Saeed | Founder, Chief Executive Officer, President and Executive Co-Chairman |
| Anthony John Durkacz | Founder and Executive Co-Chairman |
| Nathan Coyle CPA | Chief Financial Officer |
| Maryann Adesso | Corporate Secretary |
| Randell Mack | President of FSD BioSciences |
| Dr. Andrzej Chruscinski M.D., Ph.D. | Vice President of Clinical and Scientific Affairs of Lucid |
| Kevin Cassidy | Vice President of Quality-Lucid |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 8, 2024 | 6-K | Report of foreign issuer |
| Jul 8, 2024 | 6-K | Report of foreign issuer |
| Jun 28, 2024 | 6-K | Report of foreign issuer |
| Jun 28, 2024 | 6-K | Report of foreign issuer |
| Jun 27, 2024 | 6-K | Report of foreign issuer |
| Jun 13, 2024 | 6-K | Report of foreign issuer |
| Jun 4, 2024 | 6-K | Report of foreign issuer |
| May 31, 2024 | 6-K | Report of foreign issuer |
| May 28, 2024 | 6-K | Report of foreign issuer |
| May 24, 2024 | 6-K | Report of foreign issuer |